000			03708nam a22004215i 4500
001			60031
005			20200226102531.0
007			cr nn 008mamaa
008			161028s2017 gw | s |||| 0|eng d
020			_a9783319404004 _9978-3-319-40400-4
024	7		_a10.1007/978-3-319-40400-4 _2doi
035			_a(DE-He213)978-3-319-40400-4
050		4	_aRS1-441
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a353.998 _223
245	1	0	_aPharmacovigilance _h[electronic resource] : _bCritique and Ways Forward / _cedited by I. Ralph Edwards, Marie Lindquist.
264		1	_aCham : _bSpringer International Publishing : _bImprint: Adis, _c2017.
300			_aXXXI, 205 p. 16 illus., 3 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_a1. How to learn Pharmacovigilance, now and in the Future -- 2. Lost in Regulation -- 3. What is the Future of Pharmacovigilance and how can we Make it as Good as Possible? -- 4. Some Other Ideas About the Future of Pharmacovigilance -- 5. Best Safety Practices now and in the Future -- 6. Is There a Benefit from the Medical Literature Monitoring Service of the EMA? -- 7. The Unified Drug Safety-Clinical Database -- 8. Behind the Scenes – ‘Silent Factors’ Influencing Pharmacovigilance Practice and Decisions -- 9. Shaking up Culture and Communication in PV [V6] -- 10. Broadening the Scope of Pharmacovigilance -- 11. Effective Treatment Matters: Revitalizing Pharmacoviglance -- 12. There are More Weber-Effects -- 13. Herbal and Traditional Medicines, Now and Future -- 14. The Concept of ‘Health’ -- 15. Impact of Referral Procedures on the Interaction of RMP and PSUR -- 16. Other Sources of Information for Monitoring Drug Safety: Now and in the Future -- 17. Ecopharmacovigilance.
520			_aWritten by experienced authors, this book offers expert personal views on what the current problems in pharmacovigilance are and how they should be solved. This book stems from thoughts and ideas discussed in a series of meetings of the International Society of Pharmacovigilance (ISoP), where concerns were raised that the current pharmacovigilance system is not delivering optimally to improve therapeutics in clinical practice. Pharmacovigilance of the future must be an active and integral part of health care delivery, and focus more on science and practices that support health professionals and patients in day-to-day care situations. To achieve this, a dynamic and sustainable development of vigilance must take precedence over the current excessive preoccupations with data processing and regulations; all aspects of medicines use and their effects need to be considered; and all stakeholders must be involved and engaged in an open and constructive debate. The work is essential reading for anyone who has an interest in safer use of medicines. It is intended to be equally challenging and rewarding, and sets out to stimulate a continuous debate on how pharmacovigilance can better meet the needs of health professionals and patients to achieve the aim of wise therapeutic decision making.
650		0	_aMedicine.
650		0	_aPharmacy.
650	1	4	_aMedicine & Public Health.
650	2	4	_aDrug Safety and Pharmacovigilance.
700	1		_aEdwards, I. Ralph. _eeditor.
700	1		_aLindquist, Marie. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783319403991
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-319-40400-4
912			_aZDB-2-SME
999			_c6473 _d6473